筛查的因果与非因果成分对前列腺癌死亡率的影响:ERSPC中介分析
基于ERSPC试验中芬兰、荷兰和瑞典三个中心的数据,对8046、3701和1382例55-69岁确诊前列腺癌男性进行中介分析。16年随访显示,筛查组前列腺癌特异性限制平均生存时间(RMST)绝对增加分别为0.13年(95%CI 0.05-0.22)、0.48年(95%CI 0.24-0.62)和0.44年(95%CI 0.22-0.68),该效应主要归因于诊断时的风险分组而非治疗。
要点
- PSA筛查降低前列腺癌特异性死亡率,效应主要由诊断时风险分组中介。
- 诊断时的治疗未显著中介筛查对前列腺癌特异性生存的改善。
- 三个中心筛查组16年RMST绝对增加0.13-0.48年不等。
核心结论
- PSA筛查通过早期发现预后更好的前列腺癌并改善后续治疗结局来降低前列腺癌特异性死亡率。
- 观察到的结果确为筛查的因果效应。
研究设计与样本
- 基于ERSPC随机对照试验的中介分析,纳入芬兰8046例、荷兰3701例、瑞典1382例55-69岁确诊前列腺癌男性。
主要发现
- 筛查组 vs 对照组16年前列腺癌特异性RMST绝对增加:芬兰0.13年(95%CI 0.05-0.22),荷兰0.48年(95%CI 0.24-0.62),瑞典0.44年(95%CI 0.22-0.68)。
- 效应主要归因于诊断时的风险分组,而非诊断时的治疗。
临床怎么用
- 支持PSA筛查通过早期发现预后更好的肿瘤来降低前列腺癌死亡率,临床应关注筛查带来的分期迁移和治疗改善。
局限性
- 仅纳入ERSPC三个最大的中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown that prostate-specific antigen (PSA)-based screening reduces prostate cancer (PCa)-specific mortality (PCSM). However, the mediating role of a stage shift and curative treatment in the causal pathway from screening to reduced PCSM has not been elucidated. METHODS: In the ERSPC trial, men were randomly allocated to either a screening arm, with regular PSA measurements, or a control arm. During 16-yr follow-up, 8046 men from Finland, 3701 from the Netherlands, and 1382 from Sweden were diagnosed with PCa and were aged 55-69 yr at the time of randomization. A directed acyclic graph was used to define the impact of screening on the PCa-specific restricted mean survival time (RMST) after randomization, mediated by risk group and treatment at diagnosis. KEY FINDINGS AND LIMITATIONS: The absolute increase in RMST over 16 yr for men in the screening arm versus the control arm was 0.13 yr (95% confidence interval [CI] 0.05-0.22) in Finland, 0.48 yr (95% CI 0.24-0.62) in the Netherlands, and 0.44 yr (95% CI 0.22-0.68) in Sweden. This effect was mainly attributable to risk group at diagnosis, and not through treatment at the time of diagnosis. A limitation of the study is that we only included the three largest ERSPC centers. CONCLUSIONS AND CLINICAL IMPLICATION: The reduced PCSM achieved by early PCa detection via PSA-based screening is caused by more favorable prognostic features and subsequent improved treatment outcomes. Our findings confirm that the observed results are a causal effect of screening.
引用
- Remmers S, Talala K, Roobol MJ, et al. Effects of Causal and Noncausal Components of Screening on Prostate Cancer Mortality: A Mediation Analysis from the Dutch, Finnish, and Swedish Centers of the European Randomized Study of Screening for Prostate Cancer. Eur Urol Oncol. 2026. PMID: 41507018. doi:10.1016/j.euo.2025.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。